Therapeutic efficacy of the Qing Dai in patients with intractable ulcerative colitis

Table 1 Patient characteristics including lesion type and ulcerative colitis duration and treatment

Patient	Sex	Age (yr)	Type of UC Lesion	Duration of UC (mo)	Ongoing treatment at time of Qing Dai initiation
A	M	16	Proctitis	18	5-ASA, PSL
B	M	36	Left-sided colitis	65	5-ASA, IFX
C	M	35	Proctitis	96	5-ASA, PSL, CAP
D	M	33	Pancolitis	60	5-ASA, PSL, AZA, IFX
E	M	31	Left-sided colitis	40	5-ASA, PSL, AZA
F	M	27	Left-sided colitis	32	5-ASA, PSL, CAP, IFX
G	F	26	Proctitis	6	5-ASA
H	F	29	Left-sided colitis	8	5-ASA, PSL
I	M	75	Left-sided colitis	74	5-ASA, PSL, AZA

Nine UC patents (7 men and 2 women) were included in this study. The type of colitis lesion, the duration of UC and the ongoing treatment at the time of Qing Dai initiation are shown. UC: Ulcerative colitis; M: Male; F: Female; 5-ASA: 5-aminosalicylates; PSL: Prednisolone; IFX: Infliximab; CAP: Cytapheresis; AZA: Azathioprine.